静脉用贝利尤单抗治疗活动性自身抗体阳性系统性红斑狼疮的死亡与特殊关注不良事件:BASE 4 期随机对照试验
BASE 是一项在 33 个国家开展的双盲、随机、安慰剂对照 4 期试验,纳入 4018 例活动性 SLE 成人患者,按 1:1 随机接受静脉贝利尤单抗 10 mg/kg 或安慰剂联合标准治疗 48 周。结果显示两组全因死亡率和多数特殊关注不良事件发生率相似,但贝利尤单抗组严重抑郁、治疗中出现的自杀倾向及申办方判定的严重自杀或自伤事件比例较高。
要点
- 严重感染、机会性感染及恶性肿瘤发生率两组相似。
- 贝利尤单抗组严重抑郁及申办方判定的严重自杀或自伤事件比例较高,需关注。
核心结论
- 贝利尤单抗组与安慰剂组全因死亡率和特殊关注不良事件总体发生率相似。
- 但贝利尤单抗组严重输液或过敏反应、严重抑郁、治疗中出现的自杀倾向及申办方判定的严重自杀或自伤事件比例较高。
研究设计与样本
- BASE 为双盲、随机、安慰剂对照 4 期试验,在 33 个国家开展。
- 活动性 SLE 成人按 1:1 随机接受静脉贝利尤单抗 10 mg/kg 或安慰剂联合标准治疗 48 周。
- 安全性分析基于实际治疗人群,贝利尤单抗组 2002 例,安慰剂组 2001 例。
关键数值与推荐
- 主要终点为治疗期间(首次至末次研究药物给药后 28 天)全因死亡率和特殊关注不良事件的发生率。
临床怎么用
- 使用贝利尤单抗治疗活动性 SLE 时,除常规监测感染和恶性肿瘤外,应关注严重抑郁、自杀倾向及严重自杀或自伤事件。
- 输液或过敏反应、严重抑郁等事件虽发生率低,但贝利尤单抗组数值高于安慰剂组,临床需保持警惕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Belimumab is approved for the treatment of active systemic lupus erythematosus (SLE). Although clinical trials showed a favourable benefit-risk profile, numerical differences in the incidence of mortality and adverse events of special interest (AESIs) have been reported. We assessed the frequency of these events in patients with SLE receiving belimumab or placebo plus standard therapy. METHODS: BASE was a double-blind, randomised, placebo-controlled, phase 4 trial done in 33 countries. Adults with active SLE were randomly assigned (1:1) to receive intravenous belimumab (10 mg/kg) or placebo, plus standard therapy, for 48 weeks. The primary endpoints were incidences of all-cause mortality and AESIs during the on-treatment period (first-to-last study drug dose + 28 days). Safety analyses were done in the as-treated population (patients grouped by actual treatment received >50% of the time). This study was registered with ClinicalTrials.gov (NCT01705977). FINDINGS: Between Nov 27, 2012, and July 28, 2017, we randomly assigned 4018 patients. The as-treated population included 2002 patients in the belimumab group versus 2001 in the placebo group. Ten (0·50%) patients in the belimumab group died versus eight (0·40%) in the placebo group (difference 0·10%, 95% CI -0·31 to 0·51). Incidences were similar in the belimumab and placebo groups for serious infections (75 [3·75%] of 2002 vs 82 [4·10%] of 2001; difference -0·35%, 95% CI -1·55 to 0·85), opportunistic infections and other infections of interest (36 [1·80%] vs 50 [2·50%]; -0·70%, -1·60 to 0·20), non-melanoma skin cancers (4 [0·20%] vs 3 [0·15%]; 0·05%, -0·21 to 0·31) and other malignancies (5 [0·25%] vs 5 [0·25%]; 0·00%, -0·31 to 0·31). A higher proportion of patients in the belimumab group than in the placebo group had infusion and hypersensitivity reactions (8 [0·40%] vs 2 [0·10%]; 0·30%, -0·01 to 0·61), serious depression (7 [0·35%] vs 1 [0·05%]; 0·30%, 0·02 to 0·58), treatment-emergent suicidality (28 [1·42%] of 1972 patients vs 23 [1·16%] of 1986; 0·26%, -0·44 to 0·96), and sponsor-adjudicated serious suicide or self-injury (15 [0·75%] of 1972 patients vs 5 [0·25%] of 1986; post hoc difference 0·50%, 0·06 to 0·94). INTERPRETATION: In line with previously published data, incidences of all-cause mortality and AESIs were similar in patients given belimumab and placebo, except for serious infusion or hypersensitivity reactions, serious depression, treatment-emergent suicidality, and sponsor-adjudicated serious suicide or self-injury events. FUNDING: GSK.
引用
- Sheikh SZ, Scheinberg MA, Wei JC, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2020. PMID: 38279368. doi:10.1016/S2665-9913(20)30355-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。